Trial · NCT01127581
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to Vaginal Delivery During the First Hospital Admission | Interval from study drug administration to vaginal delivery (average 24 hours) | |
| Primary | Incidence of Cesarean Delivery During the First Hospital Admission | Interval from study drug administration to cesarean delivery (average 24 hours) | |
| Secondary | Time to Any Delivery (Vaginal or Cesarean) During the First Hospital Admission | Interval from study drug administration to neonate delivery (average 24 hours) | |
| Secondary | Time to Active Labor During the First Hospital Admission | Interval from study drug administration to active labor (average 12 hours) | Active labor was defined as progressive cervical dilatation to 4 cm with any frequency of contractions OR rhythmic, firm, adequate quality uterine contractions causing progressive cervical change occurring at a frequency of 3 or more in 10 minutes and lasting 45 seconds or more. |
| Secondary | Incidence of Pre-delivery Oxytocin During the First Hospital Admission | At least 30 minutes after study drug removal | Percentage of participants in receipt of Oxytocin for induction after study drug removal. |
| Secondary | Incidence of Vaginal Delivery Within 12 Hours | Interval from study drug administration to vaginal delivery within 12 hours | |
| Secondary | Incidence of Any Delivery Within 24 Hours | Interval from study drug administration to delivery of neonate within 24 hours | |
| Secondary | Incidence of Any Delivery Within 12 Hours | Interval from study drug administration to delivery of neonate within 12 hours | |
| Secondary | Incidence of Vaginal Delivery Within 24 Hours | Interval from study drug administration to vaginal delivery within 24 hours | |
| Secondary | Incidence of Vaginal Delivery | Interval from study drug administration to vaginal delivery (average 24 hours) | |
| Secondary | Rate of Adverse Events | From study drug administration to hospital discharge (approximately 48-72 hours) | All adverse events were rated by the Investigator as mild, moderate or severe and classified as having no relationship, possible relationship or a probable relationship to the study drug. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01127581/registered